Back to discover
Disease

Vaccine-Preventable Diseases

Late-stage therapeutic developmentEmerging research
MeSHVaccine-Preventable Diseases
3
Publications
11
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
11
All trials
4
Active
5
Late-stage
6
Completed
Late-stage studies

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and Older

Phase 3 · Recruiting · Beijing Luzhu Biotechnology Co., Ltd.

Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Thai Children and Adolescents Lacking Protective Antibody Levels After a Single Dose of Live-attenuated Hepatitis A Vaccine

Phase 3 · Active, not recruiting · Chiang Mai University

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Phase 4 · Completed · Helsinki University Central Hospital

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Phase 4 · Completed · Novavax

Comparison of Immunogenicity and Safety of Inactivated and Live-attenuated Hepatitis A Virus Vaccine Among Thai Healthy Children and Adolescents: A Randomized, Active-controlled, Open-label, Non-inferiority Trial

Phase 3 · Completed · Chiang Mai University
Recently completed

Phase 2a, Single Center, Randomized, Double-blind, Study to Evaluate the Immunogenicity and Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (180µg or 480μg) Given Intramuscularly (IM), Either as a Booster or a Primary Vaccination in Healthy Adults Previously Administered With OVX836, Influvac Tetra® or Placebo in the OVX836-002 (EudraCT Number: 2019-002939-28) and OVX836-003 (EudraCT Number: 2021-002535-39) Studies.

Phase 2 · Completed · Osivax

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Phase 4 · Completed · Novavax

Comparison of Immunogenicity and Safety of Inactivated and Live-attenuated Hepatitis A Virus Vaccine Among Thai Healthy Children and Adolescents: A Randomized, Active-controlled, Open-label, Non-inferiority Trial

Phase 3 · Completed · Chiang Mai University

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Phase 4 · Completed · Helsinki University Central Hospital

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Phase 2 · Completed · Dynavax Technologies Corporation

A Randomized, Open-labelled, Parallel, Phase 1 Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Hepatitis B Vaccine CVI-HBV-002 in Adults

Phase 1 · Completed · CHA Vaccine Institute Co., Ltd.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20242025
Major themes8
  • Vaccine-Preventable Diseases2
  • Arbovirus Infections1
  • Communicable Diseases1
  • Disability-Adjusted Life Years1
  • Immunity, Cellular1
  • Neglected Diseases1
  • T-Lymphocytes1
  • Vaccines1
Leading journals3
  • BMC infectious diseases1
  • Human vaccines & immunotherapeutics1
  • Scientific reports1
Leading researchers8
  • Bolotin S1
  • Corrado M1
  • Crespo C1
  • Diaz-Aguiló A1
  • Kamu T1
  • Lau CL1
  • Lawford HLS1
  • López-Belmonte JL1
Affiliations (unnormalised)6
  • Carlos III University1
  • Center for Vaccine Preventable Diseases1
  • Department of Laboratory Medicine and Pathobiology1
  • National University of Samoa1
  • Oceania University of Medicine1
  • Tupua Tamasese Meaole Hospital1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Diseases for which vaccines exist that can confer partial or complete protection. (World Health Organization vaccine-safety-training.org)

Identifiers
MeSHVaccine-Preventable Diseases
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.